Cas no 71125-38-7 (Meloxicam)

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) exhibiting potent analgesic and anti-inflammatory properties through its selective inhibition of cyclooxygenase-2 (COX-2). It offers rapid onset of action, sustained efficacy, and favorable gastrointestinal safety profile, making it a suitable option for managing moderate to severe osteoarthritis pain.
Meloxicam structure
Meloxicam structure
Product Name:Meloxicam
CAS No:71125-38-7
MF:C14H13N3O4S2
MW:351.4007
MDL:MFCD00868752
CID:59177
PubChem ID:87560523
Update Time:2025-08-01

Meloxicam Chemical and Physical Properties

Names and Identifiers

    • Meloxicam
    • MeloxicamUsp27
    • 4-Hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazin-3-crboxamide 1,1-dioxide
    • MeloxicaM, BP
    • Meloxicam (400 mg)
    • MeloxicaM API
    • MeloxicaM (Mobic)
    • 4-Hydroxy-2-Methyl-N-(5-Methylthiazol-2-yl)-2H-benzo[e][1,2]thiazine-3-carboxaMide 1,1-dioxide
    • 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-1,1-dioxide-2H-1,2-benzothiazine-3-carboxamide
    • 4-Hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
    • Meloxciam
    • METACAM
    • MOBEC
    • MOBIC
    • Mobicox
    • Movalis
    • Movatec
    • Parocin
    • structure was taken from Chemical Abstracts Index Guide, number
    • 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
    • Meloxicamum
    • Meloxicamum [Latin]
    • Tenaron
    • C14H13N3O4S2
    • VG2QF83CGL
    • MLS00
    • 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benothiazine-3-carboxamide 1,1-dioxide
    • GTPL7220
    • UHAC-62XX
    • Rheumocam
    • DTXSID1020803
    • s1734
    • F20356
    • Meloxicam Injection
    • MLS001304725
    • NCGC00018248-01
    • AB00383033_20
    • AN-668/13244001
    • 4-hydroxy-2-methyl-N-(5-methyl-2-thiazole)-2H-1,2-benzothiazine-3 -carboxamide 1,1-dioxide
    • KBio2_004681
    • UH-AC 62XX
    • Tox21_111734
    • MELOXICAM COMPONENT OF ZELERIS
    • NCGC00018248-02
    • NCGC00018248-08
    • EN300-52507
    • KS-1084
    • F2173-0387
    • HY-B0261
    • MELOXICAM [WHO-DD]
    • ZRVUJXDFFKFLMG-UHFFFAOYSA-N
    • DB00814
    • AB00383033-18
    • Mobic (TN)
    • KBio2_007249
    • Melfax
    • CCG-39098
    • Recocam
    • MELOXICAM [EMA EPAR VETERINARY]
    • BCP11928
    • Spectrum3_000649
    • Metacam Oral Suspension
    • NS00000018
    • Meloxicam (JAN/USP/INN)
    • Q414028
    • 4-Hydroxy-2-methyl-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid (5-methyl-thiazol-2-yl)-amide
    • N1539
    • SPECTRUM1504150
    • KBioSS_002113
    • HSDB 7741
    • MELOXICAM [VANDF]
    • Meloxidyl
    • Meloxicamum (Latin)
    • (3E)-3-[hydroxy-[(5-methyl-1,3-thiazol-2-yl)amino]methylidene]-2-methyl-1,1-dioxo-1lambda6,2-benzothiazin-4-one
    • HMS3713I19
    • Melonex
    • SMR000718800
    • QMIIZ ODT
    • HMS2234P07
    • Meloxicam (USAN:USP:INN:BAN)
    • Tox21_302756
    • miloxicam
    • CHEMBL599
    • HMS3655K06
    • UNII-VG2QF83CGL
    • MELOXICAM [USP-RS]
    • Meloxicam - CAS 71125-38-7
    • AKOS000279442
    • Spectrum2_000941
    • AKOS026749959
    • ZELERIS COMPONENT MELOXICAM
    • Tox21_111734_1
    • NCGC00018248-05
    • Meloxicam Solution for Injection
    • NCGC00018248-03
    • (E)-3-(hydroxy((5-methylthiazol-2-yl)amino)methylene)-2-methyl-2,3-dihydro-4H-benzo[e][1,2]thiazin-4-one 1,1-dioxide
    • Coxflam
    • MELOXICAM [EP MONOGRAPH]
    • KBioGR_001234
    • N-1539
    • C08169
    • 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide
    • HMS2089B18
    • ANJESO
    • HMS3744K09
    • MELOXICAM [MART.]
    • MELOXICAM [JAN]
    • NS00114268
    • MELOXICAM [MI]
    • FT-0628193
    • Z1695493323
    • MFCD00868752
    • SCHEMBL3576
    • SMR000058994
    • Melovem
    • CAS-71125-38-7
    • SCHEMBL23589638
    • Contacera
    • MLS000028587
    • ETI-511
    • SCHEMBL33369
    • HMS3372C13
    • Meloxicam,(S)
    • NC00698
    • NCGC00018248-26
    • NCGC00263878-02
    • SR-01000003132-10
    • 2H-1,2-Benzothiazine-3-carboximidic acid, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide
    • MLS006011422
    • MELOXICAM [HSDB]
    • MELOXICAM [GREEN BOOK]
    • UH-AC-62 XX
    • Meloxicam 1.0 mg/ml in Dimethyl Sulfoxide
    • SCHEMBL713100
    • 4-Hydroxy-2-methyl-N-(5-methylthiazol-2-yl)-2H-benzo[e][1,2]thiazine-3-carboxamide1,1-dioxide
    • Meloxoral
    • Coxicam
    • MELOXICAM [ORANGE BOOK]
    • 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
    • Loxicom
    • 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1$l^{6},2-benzothiazine-3-carboxamide
    • MELOXICAM [USAN]
    • 4-hydroxy-2-methyl-N-(5-methy-2-thiazolyl)-2H-1,2-benzothiazine-3-caboxamide-1,1-dioxide
    • 4-Hydroxy-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid (5-methyl-thiazol-2-yl)-amide
    • D00969
    • RevitaCAM
    • Spectrum5_001813
    • 133687-22-6
    • NCGC00018248-06
    • HMS3884G08
    • Meloxicam impurity standard
    • 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide
    • CCRIS 9139
    • Ostilox
    • Opera_ID_2
    • BIDD:GT0726
    • KBio3_001477
    • BSPBio_002257
    • A837087
    • AB00383033-17
    • NCGC00022924-03
    • Acticam
    • Spectrum_001633
    • SMP2_000133
    • NCGC00018248-07
    • 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1lambda6,2-benzothiazine-3-carboxamide
    • Spectrum4_000787
    • MELOXICAM (EMA EPAR VETERINARY)
    • NCGC00256316-01
    • MELOXICAM (EP MONOGRAPH)
    • MELOXICAM [INN]
    • MELOXICAM (USP-RS)
    • HMS2236C09
    • NCGC00018248-10
    • 3-{hydroxy[(5-methyl-1,3-thiazol-2-yl)amino]methylidene}-2-methyl-3,4-dihydro-2H-1lambda6,2-benzothiazine-1,1,4-trione
    • M1959
    • Emdocam
    • Inflacam
    • NCGC00018248-23
    • NCGC00018248-04
    • SPBio_000902
    • HSCI1_000045
    • ZYNRELEF COMPONENT MELOXICAM
    • HMS3372P18
    • Tox21_201689
    • Metacam 5 mg/mL Solution for Injection
    • M01AC06
    • 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1$l^{6},2-benzothiazine-3-carboxamide
    • Vivlodex
    • NCGC00259238-01
    • KBio2_002113
    • Meloxicam 100 microg/mL in Acetonitrile
    • CHEMBL1741042
    • Revmoksikam
    • MELOXICAM COMPONENT OF ZYNRELEF
    • 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methylthiazolyl)-, 1,1-dioxide
    • NCGC00018248-25
    • Lopac0_000766
    • BH164661
    • OroCAM Transmucosal Oral Spray
    • HMS1922D19
    • Meloxidolor
    • CHEBI:6741
    • Meloxivet
    • HMS2096I19
    • Melosus
    • (3Z)-2-methyl-3-[[(5-methyl-1,3-thiazol-2-yl)amino]-oxidanyl-methylidene]-1,1-bis(oxidanylidene)-1$l^{6},2-benzothiazin-4-one
    • MLS001306413
    • 71125-38-7
    • Alloxate
    • DTXCID70803
    • SW219562-1
    • MELOXICAM [USP MONOGRAPH]
    • Flexicam
    • AC-1325
    • (3Z)-3-[hydroxy-[(5-methyl-2-thiazolyl)amino]methylidene]-2-methyl-1,1-dioxo-1$l^{6},2-benzothiazin-4-one
    • Meloxicam 1000 microg/mL in Acetonitrile
    • Meloxicam [USAN:USP:INN:BAN]
    • HMS3259H06
    • MELOXICAM (MART.)
    • Tox21_113192
    • BDBM50056998
    • NCGC00022924-04
    • AMY40407
    • MELOXICAM (USP MONOGRAPH)
    • DB-055490
    • NCGC00018248-24
    • STK620505
    • BBL029076
    • ALBB-027268
    • MDL： MFCD00868752
    • Inchi： 1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19)
    • InChI Key： ZRVUJXDFFKFLMG-UHFFFAOYSA-N
    • SMILES： S1(C2=CC=CC=C2C(=C(C(NC2=NC=C(C)S2)=O)N1C)O)(=O)=O

Computed Properties

  • Exact Mass: 351.03500
  • Monoisotopic Mass: 351.034747
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 2
  • Hydrogen Bond Acceptor Count: 7
  • Heavy Atom Count: 23
  • Rotatable Bond Count: 2
  • Complexity: 628
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 0
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Surface Charge: 0
  • Tautomer Count: 8
  • XLogP3: 3
  • Topological Polar Surface Area: 136

Experimental Properties

  • Color/Form: Light yellow powder.
  • Density: 1.613
  • Melting Point: 255°C(lit.)
  • Boiling Point: No data available
  • Flash Point: No data available
  • Refractive Index: 1.72
  • Solubility: DMSO: soluble
  • Water Partition Coefficient: Soluble in water (22 mg/ml), DMSO (25 mg/ml), DMF, acetone(slightly soluble), ethanol(slightly soluble), and methanol(slightly soluble).
  • Stability/Shelf Life: Stable. Incompatible with strong oxidizing agents.
  • PSA: 136.22000
  • LogP: 3.04260
  • Merck: 5826
  • pka: 4.08 in water; 4.24 ± 0.01 in water/ethanol (1:1); 4.63 ± 0.03 in water/ethanol (1:4)
  • Solubility: Not determined

Meloxicam Security Information

Meloxicam Customs Data

  • HS CODE：2934999090
  • Customs Data：

    China Customs Code:

    2934999090

    Overview:

    2934999090. Other heterocyclic compounds. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%

    Declaration elements:

    Product Name, component content, use to

    Summary:

    2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Meloxicam Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
MedChemExpress
HY-B0261-10mM*1mLinDMSO
Meloxicam
 71125-38-7 99.70%
10mM*1mLinDMSO
 ￥375 2023-07-26
MedChemExpress
HY-B0261-100mg
Meloxicam
 71125-38-7 99.59%
100mg
 ￥350 2025-04-16
MedChemExpress
HY-B0261-500mg
Meloxicam
 71125-38-7 99.59%
500mg
 ￥850 2025-04-16
TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd.
M1959-25G
Meloxicam
 71125-38-7 >98.0%(HPLC)
25g
 ￥440.00 2024-04-15
Fluorochem
M02128-1g
Meloxicam
 71125-38-7 >99%
1g
 ￡10.00 2022-02-28
Fluorochem
M02128-10g
Meloxicam
 71125-38-7 >99%
10g
 ￡15.00 2022-02-28
Fluorochem
M02128-25g
Meloxicam
 71125-38-7 >99%
25g
 ￡30.00 2022-02-28
HE FEI BO MEI SHENG WU KE JI YOU XIAN ZE REN GONG SI
MM6289-100g
Meloxicam
 71125-38-7 ≥99%
100g
 ￥980元 2023-09-15
HE FEI BO MEI SHENG WU KE JI YOU XIAN ZE REN GONG SI
MM6289-25g
Meloxicam
 71125-38-7 ≥99%
25g
 ￥390元 2023-09-15
HE FEI BO MEI SHENG WU KE JI YOU XIAN ZE REN GONG SI
MM6289-5g
Meloxicam
 71125-38-7 ≥99%
5g
 ￥180元 2023-09-15

Meloxicam Production Method

Meloxicam Suppliers

Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:71125-38-7)美洛昔康
Order Number:LE8380135;LE12777;LE1490
Stock Status:in Stock
Quantity:25KG,200KG,1000KG
Purity:99%
Pricing Information Last Updated:Friday, 20 June 2025 12:46
Price ($):discuss personally
Amadis Chemical Company Limited
Gold Member
Audited Supplier Audited Supplier
(CAS:71125-38-7)Meloxicam
Order Number:A837087
Stock Status:in Stock
Quantity:100g
Purity:99%
Pricing Information Last Updated:Friday, 30 August 2024 06:39
Price ($):157.0
Zhengzhou Baoyu Pharmaceutical Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
(CAS:71125-38-7)Meloxicam
Order Number:LE273
Stock Status:in Stock
Quantity:5KG/1KG/25KG/100KG
Purity:99% HPLC
Pricing Information Last Updated:Thursday, 14 August 2025 14:44
Price ($):negotiated

Meloxicam Spectrogram

MS-MS
MS-MS
1H NMR 300 MHz DMSO
1H NMR
13C NMR
13C NMR

Meloxicam Related Literature

Related Categories

Additional information on Meloxicam

Meloxicam (CAS No. 71125-38-7): A Comprehensive Guide to Its Properties, Uses, and Market Trends

Meloxicam (CAS No. 71125-38-7) is a widely recognized nonsteroidal anti-inflammatory drug (NSAID) that has gained significant attention in the pharmaceutical and healthcare industries. Known for its potent anti-inflammatory, analgesic, and antipyretic properties, Meloxicam is commonly prescribed for the treatment of osteoarthritis, rheumatoid arthritis, and other inflammatory conditions. This article delves into the chemical properties, therapeutic applications, and current market trends of Meloxicam, providing a thorough understanding of its role in modern medicine.

The chemical structure of Meloxicam is characterized by its thiazine-carboxamide moiety, which contributes to its selective inhibition of cyclooxygenase-2 (COX-2). This selectivity reduces the risk of gastrointestinal side effects, a common issue with traditional NSAIDs. With a molecular formula of C14H13N3O4S2 and a molecular weight of 351.4 g/mol, Meloxicam exhibits excellent solubility in organic solvents, making it suitable for various pharmaceutical formulations.

One of the most frequently searched questions about Meloxicam is its mechanism of action. Unlike non-selective NSAIDs, Meloxicam preferentially inhibits COX-2, an enzyme responsible for prostaglandin synthesis during inflammation. This targeted action minimizes adverse effects on the gastrointestinal tract while maintaining efficacy. Patients and healthcare providers often inquire about the dosage of Meloxicam, which typically ranges from 7.5 mg to 15 mg per day, depending on the severity of the condition.

The therapeutic applications of Meloxicam extend beyond human medicine. Veterinary practitioners frequently use Meloxicam for dogs and other animals to manage pain and inflammation associated with musculoskeletal disorders. This versatility has contributed to its growing popularity in both human and veterinary markets. Recent studies have also explored the potential of Meloxicam in treating chronic pain conditions, further expanding its scope of use.

Market trends indicate a steady rise in the demand for Meloxicam, driven by the increasing prevalence of arthritis and other inflammatory diseases. The global Meloxicam market is projected to grow at a compound annual growth rate (CAGR) of 4.5% over the next five years. Factors such as the aging population, rising healthcare expenditures, and advancements in drug delivery systems are expected to fuel this growth. Additionally, the availability of generic versions has made Meloxicam more accessible to a broader patient population.

Another hot topic surrounding Meloxicam is its safety profile. While generally well-tolerated, Meloxicam side effects can include dizziness, nausea, and, in rare cases, cardiovascular events. Patients often search for information on Meloxicam interactions with other medications, such as anticoagulants and diuretics. Healthcare providers emphasize the importance of monitoring and adjusting dosages to mitigate these risks.

In recent years, researchers have focused on developing novel formulations of Meloxicam, such as transdermal patches and sustained-release tablets, to enhance patient compliance and reduce dosing frequency. These innovations align with the growing trend toward personalized medicine and improved drug delivery systems. The future of Meloxicam looks promising, with ongoing clinical trials exploring its efficacy in new therapeutic areas.

For those interested in the synthesis of Meloxicam, the process involves multi-step organic reactions, including condensation and cyclization. The purity and quality of Meloxicam API (Active Pharmaceutical Ingredient) are critical to ensuring its safety and efficacy. Regulatory agencies such as the FDA and EMA have established stringent guidelines for the production and quality control of Meloxicam to meet global standards.

In conclusion, Meloxicam (CAS No. 71125-38-7) remains a cornerstone in the management of inflammatory and pain-related conditions. Its selective COX-2 inhibition, broad therapeutic applications, and evolving market dynamics make it a subject of ongoing interest and research. Whether you are a healthcare professional, researcher, or patient, understanding the nuances of Meloxicam can help optimize its use and contribute to better health outcomes.

71125-38-7 (Meloxicam) Related Products

Recommended suppliers
Tiancheng Chemical (Jiangsu) Co., Ltd
(CAS:71125-38-7)美洛昔康
LE8380135;LE12777;LE1490
Purity:99%/99%/99%
Quantity:25KG,200KG,1000KG/25KG,200KG,1000KG/25KG,200KG,1000KG
Price ($):Inquiry/Inquiry/Inquiry
Email
Amadis Chemical Company Limited
(CAS:71125-38-7)Meloxicam
A837087
Purity:99%
Quantity:100g
Price ($):157.0
Email